Literature DB >> 32757850

Tophaceous pseudogout in a 12-year-old dog, with a review of applicable laboratory tests.

Brittani R Henschen1, Michael R Lewin-Smith1, Pamela J Mouser2, Hazel M Jenkins1, Stacy L Strausborger1, John F Fetsch1, Elise E B LaDouceur1.   

Abstract

Pseudogout, also known as calcium pyrophosphate dihydrate (CPPD) deposition disease or chondrocalcinosis, is caused by crystalline deposits of CPPD within the extracellular matrix of articular hyaline cartilage and fibrocartilage, and within articular and periarticular connective tissue. Using a variety of laboratory techniques, we diagnosed pseudogout in the right hindlimb digit V of a 12-y-old Standard Poodle. Histologically, the joint, bone, tendon, and dermis were expanded and effaced by masses of mineralized, rhomboid crystals surrounded by macrophages, multinucleate giant cells, fibrous connective tissue, and chondroid and osseous matrix. Rhomboid crystals exhibiting weak-positive birefringence were identified under polarized light using a first-order red compensator filter. Scanning electron microscopy with energy-dispersive x-ray analysis (SEM-EDXA) revealed that the rhomboid crystals were composed of calcium, phosphorus, and oxygen. Fourier-transform infrared (FTIR) microspectroscopy confirmed the presence of calcium pyrophosphate. In dogs, tophaceous pseudogout, which was the variant of pseudogout in our case, occurs as a single, tumor-like periarticular mass that can be invasive and mimic neoplasia. Having ancillary confirmatory testing (SEM-EDXA and FTIR), particularly in unusual histologic scenarios, such as tophaceous pseudogout in dogs, is desirable for confirming the correct diagnosis, even though it is available only at certain reference centers. The pathogenesis of pseudogout is unknown.

Entities:  

Keywords:  calcium pyrophosphate dihydrate; canine; chondrocalcinosis; pseudogout; tophaceous

Mesh:

Year:  2020        PMID: 32757850      PMCID: PMC7488958          DOI: 10.1177/1040638720945307

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  9 in total

1.  Calcium pyrophosphate deposition (chondrocalcinosis) in a dog.

Authors:  M Heimann; J L Carpenter; P B Halverson
Journal:  Vet Pathol       Date:  1990-03       Impact factor: 2.221

2.  Pseudogout in a dog.

Authors:  J P Gibson; W J Roenigk
Journal:  J Am Vet Med Assoc       Date:  1972-10-15       Impact factor: 1.936

3.  Tophaceous pseudogout: a pitfall in the diagnosis of chondrosarcoma.

Authors:  N Lambrecht; S D Nelson; L Seeger; S Bose
Journal:  Diagn Cytopathol       Date:  2001-10       Impact factor: 1.582

4.  A case of tophaceous pseudogout of the temporomandibular joint extending to the base of the skull.

Authors:  K Kudoh; T Kudoh; K Tsuru; Y Miyamoto
Journal:  Int J Oral Maxillofac Surg       Date:  2016-09-16       Impact factor: 2.789

5.  Treatment and management of pseudogout: insights for the clinician.

Authors:  Paul Macmullan; Geraldine McCarthy
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

6.  Crystal identification of synovial fluid aspiration by polarized light microscopy. An online test suggesting that our traditional rheumatologic competence needs renewed attention and training.

Authors:  D Berendsen; T Neogi; W J Taylor; N Dalbeth; T L Jansen
Journal:  Clin Rheumatol       Date:  2016-11-11       Impact factor: 2.980

7.  Calcinosis circumscripta in the dog: a retrospective pathological study.

Authors:  A K Tafti; P Hanna; A C Bourque
Journal:  J Vet Med A Physiol Pathol Clin Med       Date:  2005-02

8.  Articular chondrocalcinosis of the humeral head in greyhounds.

Authors:  J C Woodard; W H Riser; A A Morrone; S R Khan
Journal:  Am J Vet Res       Date:  1995-04       Impact factor: 1.156

9.  Energy Dispersive X-ray (EDX) microanalysis: A powerful tool in biomedical research and diagnosis.

Authors:  Manuel Scimeca; Simone Bischetti; Harpreet Kaur Lamsira; Rita Bonfiglio; Elena Bonanno
Journal:  Eur J Histochem       Date:  2018-03-15       Impact factor: 3.188

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.